Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Foghorn Therapeutics' Change in Accured Expenses fell 7671.56% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 17546.83%. This contributed to the annual value of -$564000.0 for FY2024, which is 6861.44% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Change in Accured Expenses stood at $1.2 million for Q3 2025, which was down 7671.56% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Change in Accured Expenses registered a high of $5.0 million during Q3 2024, and its lowest value of -$2.8 million during Q1 2024.
  • For the 5-year period, Foghorn Therapeutics' Change in Accured Expenses averaged around $131684.2, with its median value being $690000.0 (2023).
  • As far as peak fluctuations go, Foghorn Therapeutics' Change in Accured Expenses tumbled by 1524705.88% in 2021, and later surged by 76414.47% in 2025.
  • Foghorn Therapeutics' Change in Accured Expenses (Quarter) stood at $2.4 million in 2021, then tumbled by 62.75% to $894000.0 in 2022, then tumbled by 62.86% to $332000.0 in 2023, then crashed by 829.22% to -$2.4 million in 2024, then soared by 147.79% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $2.0 million for Q2 2025, and -$2.4 million during Q1 2025.